Ph 1/2 Program Initiated for Elraglusib in refractory melanoma and additional target solid tumor and heme cancers
“With the promising results we have seen with the IV formulation of elraglusib across an array of difficult-to-treat cancers, we are excited to advance the oral tablet formulation in additional indications, including patients with R/R metastatic melanoma,” said Dan Schmitt, Chief Executive Officer of Actuate Therapeutics. “Elraglusib oral tablet will allow us to further explore elraglusib dose using a convenient and easily administered tablet dosage form that will be amenable to evaluation as a single agent. The program builds on encouraging results from our phase 1 monotherapy clinical trial with the IV formulation, including a remarkable complete response lasting more than 6 years from a patient with highly advanced, highly disseminated, refractory BRAFV600E-mutated metastatic melanoma. We believe the elraglusib oral tablet will have the potential to play an important role in addressing a significant unmet need in the treatment of refractory melanoma as well as other advanced cancer indications.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo